Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
about
Potential for developing purinergic drugs for gastrointestinal diseasesRecent developments in adenosine receptor ligands and their potential as novel drugsExciting directions in glaucomaAdenosine receptors as drug targets--what are the challenges?History of Chemistry in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).Purinergic signaling during inflammation.A single LipiFlow® Thermal Pulsation System treatment improves meibomian gland function and reduces dry eye symptoms for 9 months.A₃ adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action.Recent Patents on Emerging Therapeutics for the Treatment of Glaucoma, Age Related Macular Degeneration and Uveitis.International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an updateA review on recent advances in dry eye: Pathogenesis and managementInhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101.Pharmacological and therapeutic effects of A3 adenosine receptor agonistsCorrelation between optical coherence tomography-derived assessments of lower tear meniscus parameters and clinical features of dry eye disease.Investigational A₃ adenosine receptor targeting agents.Perioperative organ injury.Novel ocular antihypertensive compounds in clinical trials.Adenosine receptor targeting in health and disease.The A3 adenosine receptor as multifaceted therapeutic target: pharmacology, medicinal chemistry, and in silico approaches.New agents for treating dry eye syndrome.Emerging drugs for the treatment of dry eye disease.New therapeutic targets for intraocular pressure lowering.Purinergic receptors in ocular inflammation.Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.Development of Causative Treatment Strategies for Lacrimal Gland Insufficiency by Tissue Engineering and Cell Therapy. Part 1: Regeneration of Lacrimal Gland Tissue: Can We Stimulate Lacrimal Gland Renewal In Vivo?Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma.Ocular Purine Receptors as Drug Targets in the Eye.Treating ocular surface disease: new agents in developmentNovel therapeutics in glaucoma management.A Comprehensive Review on Dry Eye Disease: Diagnosis, Medical Management, Recent Developments, and Future Challenges
P2860
Q27000719-4A5165B0-35FF-4815-AE0D-C14E2A4704D9Q27687253-B618FD84-141A-486C-8842-43B35417D966Q28542397-731E8E92-1BF0-42E9-BF9E-1684E93ED7DEQ29346491-49767492-7F76-4F9E-B14A-50907F911E7BQ30370827-DC7D87C4-438A-4087-820E-49EB8CD3752DQ34034751-92396B62-FD7C-4F12-B440-6B8A60A7DE8AQ34253558-FE0A21E5-56F1-4B5A-A036-6DD92E49169EQ34412639-3A29BF71-5E16-4788-B69A-F2C2B5222BE1Q34530196-845A34E5-E2BA-4FA9-A29C-93CBD81A5435Q34701303-31AACF7D-1818-4F5E-9C2B-856071709EFDQ35176597-C89C5FD2-B1C0-49ED-BC2F-FD550F75C76CQ35197058-BF65DB8A-B688-4C00-B697-9C7764478FEFQ35788500-20EA95CA-5180-404F-96FC-69148C402D3DQ35957497-85895D61-0C0D-4FEE-ABE5-264E61E018F3Q36731575-3B49E36C-299F-427D-86AB-C179DD21B601Q37593569-394000AE-686C-4AB1-9C78-30751BA3AF42Q37883078-90F1EA1B-F9D7-414A-9D93-4318D55AD0FFQ37948081-7F0F9BD8-2FFA-4A41-99D8-D61623B3844CQ37957791-66782B79-FA7B-4F82-9E85-F3DF6977C489Q38058002-1AEDC497-D93D-4010-B8C6-B8E3B1A5A319Q38102006-8E7BBDAF-1836-43F6-A42A-A207688C8220Q38190064-DBD338BB-9FA3-40AB-9DDB-328E5795C8E7Q38240836-FF284DF9-3CF6-4922-ABCF-2D77B37D4A89Q38584194-4D5F2239-B4A9-4BA0-9D0D-E92061DCBA22Q38875664-1643AB47-60E8-4EA4-9652-591B3FCA3A01Q38934012-798EC4CC-1C09-4C68-A985-42AF1474539EQ41651208-6815E4FC-C706-469A-825B-4FB8932AB8C7Q42729437-CDF1211C-24AD-4D3E-9014-DF67B14BD430Q50023818-C551DD28-71D6-49C8-BE18-AA1BAB56C0DBQ59104204-00EB849B-90AF-45CB-BAE6-0A25DF62D69A
P2860
Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Treatment of dry eye syndrome ...... from a phase 2 clinical trial.
@ast
Treatment of dry eye syndrome ...... from a phase 2 clinical trial.
@en
Treatment of dry eye syndrome ...... from a phase 2 clinical trial.
@nl
type
label
Treatment of dry eye syndrome ...... from a phase 2 clinical trial.
@ast
Treatment of dry eye syndrome ...... from a phase 2 clinical trial.
@en
Treatment of dry eye syndrome ...... from a phase 2 clinical trial.
@nl
prefLabel
Treatment of dry eye syndrome ...... from a phase 2 clinical trial.
@ast
Treatment of dry eye syndrome ...... from a phase 2 clinical trial.
@en
Treatment of dry eye syndrome ...... from a phase 2 clinical trial.
@nl
P2093
P2860
P1433
P1476
Treatment of dry eye syndrome ...... from a phase 2 clinical trial.
@en
P2093
David R Bristol
David Varssano
David Zadok
Erez Bakshi
Fanni Segev
Gil Sartani
Gilad Litvin
Hanna J Garzozi
Irina S Barequet
P2860
P304
P356
10.1016/J.OPHTHA.2009.11.029
P577
2010-03-20T00:00:00Z